Scientists hunt for genetic signs to personalize bile duct cancer therapy
NCT ID NCT06648057
First seen Mar 23, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study is for people with advanced bile duct cancer who are already scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers will collect blood and tumor samples to look for genetic markers that might predict who benefits most from this treatment. The goal is to better understand why some patients respond well and others do not, which could help personalize care in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.